INTRODUCTION
============

Memory deficits are one of the most consistently reported cognitive difficulties in both symptomatic and remitted patients with major depressive illness ([@B28]; [@B39]; [@B3]). Given the central role of the hippocampus in the formation and consolidation of new memories ([@B13]), as well as its importance for the regulation of motivation and emotion ([@B11]), hippocampal pathology is likely to be involved in the pathophysiology of the illness. Indeed, reduced hippocampal volume has been reported by many, but not all, neuroimaging studies of MDD (major depressive disorder) ([@B9]; [@B38]). Results of a recent meta-analysis indicated that differences in hippocampal volume were only apparent among MDD patients with a duration of illness longer than 2 years, or who had more than a single disease episode, suggesting that hippocampal volume reductions typically occur after disease onset in MDD patients ([@B25]).

However, a major limitation in most prior investigations is that patients were studied while on a variety of medications. The acute and long-term effects of psychotropic medications on brain structure are not well understood. There is recent evidence for neurotrophic or neuroprotective properties of lithium ([@B4]; [@B41]), atypical antipsychotics ([@B18]; [@B37]) and antidepressant medications ([@B31]). Also, many patients with mood disorders take multiple medications, at various doses and with variable consistency over the course of the illness, and these effects are very difficult to quantify rigorously.

Finally, the question of regional specificity of hippocampal abnormalities in MDD has rarely been examined. Only one prior study, to our knowledge, has applied three-dimensional mapping methods to examine hippocampal morphology in depressed patients. In this study of patients with elderly depression, [@B2] found pronounced, localized surface contractions in patients with late-onset depression, relative to early-onset depression, although differences in overall hippocampal volumes were not detectable. Post-mortem studies have identified neuronal abnormalities in the subiculum, as well as in specific hippocampal subfields, with the most pronounced changes in the CA1 (cornu ammonis 1) region in the brains of depressed individuals ([@B29]). The CA1 region sends significant output forward to the subiculum, which has direct connections to the entorhinal cortex and the amygdala. It also projects to the ventromedial prefrontal cortex, thalamus, hypothalamus and striatum, structures critically involved in mood regulation ([@B30]).

To overcome limitations of prior investigations, we studied a group of relatively young unmedicated patients, diagnosed with MDD with no comorbidities. We used high-resolution MRI (magnetic resonance imaging) and a three-dimensional radial mapping approach to assess subregional structural deformations in the hippocampus. This technique ([@B35]) improves upon other methods in that it visualizes the spatial profile of neuropathological abnormalities, allowing more refined neuroanatomical localization of regionally specific alterations in depressed patients. We hypothesized that unmedicated depressed patients would exhibit localized alterations in hippocampal structure, relative to healthy comparison subjects, which would be most pronounced in the subiculum and CA1 subfields. Secondly, we examined relationships between hippocampal morphology and clinical variables (depression severity, family history, prior medication history and duration of illness). Given prior evidence that antidepressant and antipsychotic medications affect brain structure, we also explored the effects of previous treatment with these medications within the patient sample.

MATERIALS AND METHODS
=====================

Subjects
--------

The present study was approved by the University of Pittsburgh Biomedical Institutional Review Board. All subjects provided written informed consent, after study procedures were fully explained. In total 31 unmedicated outpatients with MDD and 31 demographically matched healthy controls were studied (see [Table 1](#T1){ref-type="table"}). Some subjects in the present study were included in previous reports that focused on other brain structures ([@B7]; [@B8]). At the time of participation in the study, all patients were off all psychotropic drugs for at least 2 weeks.

###### Demographics of patients used in the present study

Values are means±S.D. or percentages (*n*).

  Demographic                                  Unmedicated patients with unipolar depression (*n* = 31)   Healthy comparison subjects (*n* = 31)    Between-group differences
  ------------------------------------------- ---------------------------------------------------------- ---------------------------------------- ------------------------------
  Age (years)                                                         39.2±11.9                                         36.7±10.7                  *F* (1,60) = 0.73*P* = 0.40
  Female (*n*)                                                         77% (24)                                          77% (24)                      *X*^2^ = 0*P* = 1.0
  Right-handed (*n*)                                                  100% (31)                                          94% (29)                    *X*^2^ = 2.07*P* = 0.49
  Education level (years)                                              15.4±3.4                                          15.3±2.7                  *F* (1,60) = 0.55*P* = 0.40
  Race                                                                                                                                            
      Caucasian (*n*)                                                 100% (31)                                          93% (29)                     *X*^2^ = 1.0*P* = 0.60
      African-American (*n*)                                              0                                               7% (2)                                --
      Other (*n*)                                                       3% (1)                                              0                                   --
  HDRS                                                                 11.8±9.1                                             --                                  --
  Duration of illness (years)                                         11.42±10.6                                            --                                  --
  Age at onset (years)                                                27.9±11.6                                             --                                  --
  Number of episodes                                                   5.1±5.9                                              --                                  --
  Current mood state                                                                                                        --                                  --
      Depressed (*n*)                                                  65% (20)                                             --                                  --
      Euthymic (*n*)                                                   35% (11)                                             --                                  --
  Family history positive (*n*)                                        65% (20)                                             --                                  --
  Medication naïve (*n*)                                               58% (18)                                             --                                  --
  Previous atypical antipsychotic use (*n*)                            16% (5)                                              --                                  --
  Previous antidepressant use (*n*)                                    42% (13)                                             --                                  --
  Hippocampal volume (mm^3^)                                                                                                --                                  --
      Right                                                          1911.1±280.1                                      1828.9±284.2                *F* (1,59) =  2.03*P* = 0.16
      Left                                                           1885.4±230.8                                      1851.9±326.8                *F* (1,59) =  2.26*P* = 0.14

Patients met DSM-IV (Diagnostic and Statistical Manual of Mental Disorders 4th Edition) diagnostic criteria for unipolar MDD, as determined by direct interview with the SCID (Structured Clinical Interview for DSM-IV) ([@B33]). Exclusion criteria were any DSM-IV axis I comorbidity, current medical problems, history of neurological illness, history of head trauma with loss of consciousness, substance or alcohol abuse within the 6 months preceding the study, or history of substance or alcohol dependence at any time. The BRMS (Bech--Rafaelsen Mania Scale) ([@B5]) and the HDRS (Hamilton Depression Rating Scales) ([@B17]) were used to rate clinical symptoms, and were administered within a week of the MRI scan. At the time of the MRI scan, 20 subjects (65%) were in a depressed mood state, whereas 11 (35%) were euthymic. Family history information was obtained by directly questioning patients and/or relatives, and by reviewing the medical records. On the basis of this information, first-degree relatives were considered positive for mood disorders if there was a past history of ever having received a diagnosis of unipolar major depression or bipolar disorder by a physician. Patients with at least one first-degree relative with a history of mood disorders were considered familial mood disorder patients.

Healthy controls had no DSM-IV axis I disorders, as determined by direct interview with the SCID-IV-NP (SCID-IV non-patient version). They had no current medical problems and no history of psychiatric disorder among first-degree relatives. The SCID-IV interviews for patients and controls were completed by a trained clinical social worker or a registered nurse at the University of Pittsburgh Outpatient Mood Disorders Clinic. After completion of the SCID-IV interview, psychiatric diagnoses were confirmed by a board-certified study psychiatrist.

MRI procedure
-------------

MRI scans were acquired with a 1.5T GE Signa Imaging System running version Signa 5.4.3 software (General Electric Medical Systems). A sagittal scout series was first obtained to verify patient position, image quality and locate a midline sagittal image. A T1-weighted sagittal scout image was obtained for graphical prescription of the coronal and axial images. Three-dimensional gradient echo imaging (Spoiled Gradient Recalled Acquisition, SPGR) was performed in the coronal plane \[TR (repetition time), 25 ms; TE (echo time), 5 ms; FOV (field of view), 24 cm; slice thickness, 1.5 mm; NEX (number of excitations), 1; matrix size, 256 mm×192 mm\] to obtain 124 images covering the entire brain. Additionally, a double echo-spin echo sequence was used to obtain T2-weighted and proton-density images in the axial plane, to screen for neuroradiological abnormalities.

Anatomical analysis
-------------------

Individual brain volumes were reformatted in the axial plane, corrected for magnetic field inhomogeneities ([@B32]), resampled into 1-mm isotropic voxels and spatially realigned to the International Consortium for Brain Mapping non-linear average brain template (ICBM152), using FLIRT (available at <http://www.fmrib.ox.ac.uk/fsl/>). At the same time, image volumes were corrected for head-tilt and alignment with a three-translation and three-rotation rigid-body transformation (without scaling) (Woods et al., 1998), to ensure that brain measurements were not influenced by orientation. The hippocampi from each brain were traced using a software program (Tracer) ([@B40]), available at [http://www.loni.ucla.edu/Software/Software_Detail.jsp?software_id = 10](http://www.loni.ucla.edu/Software/Software_Detail.jsp?software_id=10).

Hippocampi were manually traced bilaterally by a trained image analyst, who was blinded to all demographic variables, and had established excellent reliability with 'gold standard' ratings on a training set of six pairs of hippocampi (intraclass correlation coefficient ∼0.90). This level of agreement is comparable with that obtained in prior studies ([@B6]; [@B14]). Anatomical segmentation was performed using a standard neuroanatomical atlas of the hippocampus ([@B12]) according to criteria detailed in [@B26]. Hippocampal models were delineated in contiguous coronal brain sections using standard guidelines ([@B27]), including the hippocampus proper, dentate gyrus and subiculum \[see ([@B6]; [@B14]) for further details\]. Hippocampal borders were determined by the temporal horn, choroidal fissure, uncal and ambient cisterns, and the grey/white junction between the subiculum and parahippocampal gyrus. Anatomical landmarks were followed in all three orthogonal viewing planes using interactive segmentation software. Volumes obtained from these tracings were retained for statistical analyses.

To identify regional changes in hippocampal morphology, we used surface-based anatomical mesh modelling methods that allow for precise matching of anatomy between subjects and groups at each hippocampal surface point. To do this, a gridded surface is stretched over the hippocampus, using a rectilinear mesh of equally spaced three-dimensional points along the hippocampal axis and across the upper and lower surfaces. To assess global hippocampal differences, the volumes of these three-dimensional models were measured in cubic millimetres. To measure local differences, a three-dimensional medial curve is defined along the long axis of the hippocampus and radial distance measures (i.e. the distance from homologous hippocampal surface points to the central core of the individual\'s hippocampal surface model) are estimated, as previously described in [@B6]. This procedure also allows the averaging of hippocampal surface morphological features across all individuals belonging to a group and records the amount of variation between corresponding surface points relative to the group averages. These methods reveal tissue alterations on the hippocampal surface, e.g. in regions approximately corresponding to the underlying CA1--3 subfields and subiculum/presubiculum ([@B14]; [@B4]), and are similar, in some respects, to the high-dimensional computational mapping approach developed for local shape analysis of the hippocampus ([@B10]).

Regressions were performed at each surface point to map linkages between radial size and covariates (i.e. diagnosis, age). In addition, we examined hippocampal parameters both with and without brain size correction in our statistical analyses, given that relationships between hippocampal size and brain size may differ across diagnostic groups, and our goal was to target differences specific to the hippocampus.

Uncorrected two-tailed probability values were mapped on to the averaged hippocampal surface models for the entire group and displayed in three dimensions. As statistical tests were applied at each of the hippocampal surface points, we conducted permutation-based statistics with a threshold of *P*\<0.05 to ensure that the overall pattern of effects in the surface-based maps could not have been observed by chance alone ([@B36]). For this purpose, subjects were randomly assigned to either patient or control groups 100 000 times (while keeping the number of subjects in each group the same), and a new statistical test was performed at each hippocampal surface point for each random assignment. The number of significant results from these randomizations was then compared with the number of significant results in the true assignment to produce a corrected overall significance value for the uncorrected statistical maps. Permutation was conducted both for negative disease effects (control\>MDD) and for positive disease effects (MDD\>control).

RESULTS
=======

Overall volumetric differences
------------------------------

The two groups did not differ in total brain volume, total grey matter volume or total white matter volume \[*F* (1,60) = 0.11, *P* = 0.74; *F* (1,60) = 1.4, *P* = 0.24; and *F* (1,60) = 0.67, *P* = 0.42 respectively\]. Hippocampal volumes did not differ significantly between controls and MDD subjects \[left: 1851.9±326.8 compared with 1885.4±230.8 respectively, *F* (1,59) =  2.26, *P* = 0.14; right: 1828.9±284.2 compared with 1911.1±280.1 respectively, *F* (1,59) = 2.03, *P* = 0.16\]. These results were not substantively different when controlling for total brain volume \[*F* (1,58) = 1.98, *P* = 0.12\].

Three-dimensional hippocampal maps
----------------------------------

Statistical three-dimensional maps ([Figure 1](#F1){ref-type="fig"}) indicated local differences in hippocampal structure between patients with MDD and control subjects, in terms of percentage difference and statistical significance. Although global volumes did not differ, localized increases (shown in purple) were detected in MDD patients in regions approximately corresponding to the CA1 subfields and portions of the subiculum bilaterally. However, these local differences were not significant following correction for multiple comparisons via permutation analysis (*P* = 0.10).

![Three-dimensional hippocampal maps\
(**A**) Topographical correspondence of pathology on blank MRI-based models of the hippocampal formation of normal controls, from inferior (left) and superior (right) views. Based on [@B12], where neuropathological areas are shown in seven equally spaced coronal slices spanning the entire length of the hippocampus. (**B** and **C**) Statistical three-dimensional maps indicate local differences in hippocampal structure between MDD patients and control subjects, in terms of percentage difference (**B**) and statistical significance (**C**). Purple colours indicate regions of localized increase in MDD patients compared with controls, whereas red colours indicate relative thinning in MDD patients relative to controls. Although overall volumes did not differ, localized increases (purple colours) were detected in MDD patients, in regions approximately corresponding to the CA1 subfields and portions of the subiculum/presubiculum bilaterally.](an001e020f01){#F1}

Effects of clinical variables
-----------------------------

In the overall sample, hippocampal volume was inversely correlated with age (left: *r* = −0.27, *P* = 0.03; right: *r* = −0.32, *P* = 0.01). Within the depressed group alone, age showed a similar trend-level inverse relationship with hippocampal volume (*r* = −0.35, *P* = 0.055). In addition, HDRS scores were inversely correlated with hippocampal volume within the depressed group (*r* = −0.35, *P*≤0.05), i.e. a greater severity of depressive symptoms was associated with a lower hippocampal volume. To further examine the relationship between age, depression severity and hippocampal volume, we conducted a multiple regression analysis, using age and HDRS scores as predictors of hippocampal volume. The overall model was highly significant \[*F* (1,28) = 6.31, *P* = 0.005\], and there were significant main effects of both age and HDRS score, indicating that both of these factors made significant independent contributions to hippocampal size. Categorically, those patients who were currently in a depressed mood state (HDRS≥12) had significantly smaller hippocampal volumes than those who were in a remitted state \[*F* (1,29) = 5.05, *P* = 0.03, eta^2^ = 0.15\]. These results remained significant after controlling for the effects of age (*P*≤0.05).

As age and depression severity were correlated, we examined linkages between age-adjusted HDRS score and hippocampal radial distance. Significant inverse correlations, confirmed by permutation tests, were observed between HDRS score and hippocampal surface morphology within the MDD group, such that more severe depression was associated with greater left hippocampal atrophy, particularly in the subiculum and CA1 subfields (permutation-corrected *P* values: right, *P* = 0.29; left, *P* = 0.009; [Figure 2](#F2){ref-type="fig"}).

![Correlation of hippocampal morphology with depression severity\
Three-dimensional statistical maps show significant relationships between age-adjusted HDRS score and regional hippocampal atrophy within the depressed group (left-hand depicts inferior view of the hippocampus, right-hand depicts superior view). In the significance maps (bottom panel), red and white colours denote *P* values ≤0.05. Greater depression severity was associated with greater left hippocampal atrophy, particularly in the subiculum and CA1 subfields (left, *P*~corrected~ = 0.009; right, *P*~corrected~ = 0.29).](an001e020f02){#F2}

Hippocampal structure was not significantly associated with duration of illness, the number of prior mood episodes, family history of mood disorder or past history of antidepressant use (*P*\>0.10, not significant). However, MDD patients who had previously been treated with atypical antipsychotics showed a trend toward larger hippocampi than MDD patients who were antipsychotic-naïve (permutation-corrected *P* values: left, *P* = 0.06; right, *P* = 0.07; see Supplementary Figure S1 at <http://www.asnneuro.org/an/001/an001e020add.htm>).

DISCUSSION
==========

The hippocampal maps in the present study provide novel findings regarding regional hippocampal alterations in unmedicated patients with major depression. Specifically, overall hippocampal volume was preserved in unmedicated depressed patients, concomitant with localized (non-significant) increases in CA1 subfields and portions of the subiculum bilaterally in depressed patients relative to controls. However, the sample was heterogeneous, and several clinical variables, particularly severity of depression and age, made independent contributions to hippocampal morphology and volume.

The notion that hippocampal volume reduction may be a consequence of depression has been influential in guiding recent animal, postmortem and clinical examinations of the pathophysiological basis of depression ([@B9]). The findings of the present study support this, as we find that increased depression severity was associated with left hippocampal atrophy; however, hippocampal reduction did not characterize this sample of relatively young, currently unmedicated depressed outpatients overall. Indeed, we found a trend toward increased hippocampal volume in unipolar patients previously treated with atypical antipsychotics, which may reflect postulated neuroprotective effects of these agents ([@B37]). Although caution is clearly warranted in interpreting these findings, given the small number of subjects previously treated with antipsychotics, these findings suggest that not only current drug treatment status, but past history of psychotropic medication usage, may be important in assessing structural neuroanatomical differences in patients with mood disorders.

In a large sample of bipolar patients, [@B18] found that current antipsychotic use was associated with significantly larger temporal white matter volumes; specifically, bipolar subjects taking antipsychotics had larger white matter volumes than bipolar subjects not taking antipsychotics or healthy comparison subjects. [@B31] observed that longer duration of untreated depression was associated with hippocampal volume reduction, which provides some tentative evidence that antidepressants may have a neuroprotective effect. In addition, [@B16] found a significant left hippocampal volume increase in a subgroup of depressed patients who took antidepressants over a 3-year period. In contrast, [@B42] found that medication-exposed patients with unipolar major depression, and those with multiple episodes, had smaller subgenual prefrontal cortical volumes than patients with no exposure to medication and healthy controls, suggesting that illness burden and short-term medication exposure may mediate brain alterations in anterior cingulate regions. Thus, although previous studies have observed effects of current medication use, this is the first study, to our knowledge, to suggest that prior use of atypical antipsychotics may have a persistent effect on hippocampal structure. While caution is clearly warranted in interpreting these trend-level findings, we felt that their inclusion was important to encourage investigation of such effects in other studies. To confirm this suggestive finding, longitudinal studies that assess the same individuals repeatedly over time are needed.

The results of the present study are generally consistent with a recent meta-analysis ([@B25]), which found that studies including young adult patients showed equivalent hippocampal volumes between MDD patients and controls, which may be due to reduced burden of illness in this population. In addition, other studies are consistent with ours in showing that specific clinical characteristics of the sample may affect neuroanatomical findings ([@B15]; [@B2]; [@B22]). Another recent study of medial temporal structures in major depressive illness ([@B19]) found that depressed patients with psychosis had a significantly smaller mean amygdala volume relative to depressed patients without psychosis and healthy comparison subjects, but no differences between depressed patients without psychosis and healthy comparison subjects. Similar to our findings, they observed no group differences in hippocampal volume. Nevertheless, our findings contrast with those of [@B1], who studied a comparably sized sample of unmedicated patients with major depressive illness, and found smaller posterior (but not anterior) hippocampal volume in clinically remitted MDD patients as compared with controls. Notable differences between our samples include symptomatic status, as Alexander and colleagues included only clinically remitted patients, whereas 65% of the patients in the present study were in a depressive episode at the time of investigation. In addition, although we had a similar proportion of subjects who were medication-naïve, no subjects in the [@B1] study had been previously treated with antipsychotics.

Hippocampal differences may be somewhat localized and difficult to detect in small, heterogeneous samples using global measures ([@B24]). The identification of regional alterations in hippocampal structure may thus help to elucidate the underlying pathophysiological mechanisms associated with depression, and also indicate functional systems that may be selectively disturbed in the illness. Our findings indicated depression-associated atrophy in the left hippocampus that was particularly pronounced in the subiculum and CA1 subfields. Using a rigorous measurement protocol for tracing the hippocampus, [@B23] reported differential volume loss in the tail of the hippocampus in MDD patients relative to healthy controls. This region approximately corresponds to the CA1 subfields that we found to be affected by depression severity. Notably, [@B22] also found that, in patients with recurrent MDD, larger volume in the hippocampal body/tail (but not the head) was associated with better treatment response at 8 weeks, suggesting that localized hippocampal alterations may be associated with clinical response. In a study of late-onset depression using methods similar to ours, [@B2] found that regional surface contractions were significantly pronounced in late- relative to early-onset depression, particularly in the anterior of the subiculum and lateral posterior of the CA1 subfield in the left hemisphere. These findings, as well as our own, are consistent with postmortem studies, which have identified neuronal abnormalities in the subiculum in the brains of depressed individuals ([@B29]), as well as in distinct layers of hippocampal subfields, with most pronounced changes in CA1 regions, followed by CA2 and CA3 subfields ([@B34]). The CA1 and CA2 subfields may be particularly vulnerable to vascular damage ([@B12]), which is consistent with findings of local volume reductions in late-onset depression ([@B2]) and with the hypothesis that ischaemic small-vessel disease may be implicated in the pathogenesis of elderly depression (Lyness, 2002).

Certain limitations of the present study should be noted. First, only some of the subjects were medication-naïve. Although samples were small for subgroup analyses, we nevertheless found a significant association between regional hippocampal volume reduction and depression severity, as well as a suggestive relationship between prior treatment with atypical antipsychotics and hippocampal volume. As our study was cross-sectional, it cannot be ruled out that the observed group differences were attributable to other factors. However, it is tempting to speculate that these suggestive findings may reflect postulated effects of neuropil increase related to atypical antipsychotic treatment, manifested as subtle volumetric increases on MRI. Using the same methodology for hippocampal mapping in a sample of patients with bipolar disorder, we previously found that unmedicated bipolar patients showed localized deficits in the right hippocampus, in regions corresponding primarily to the CA1 subfields, as compared with both normal controls and lithium-treated bipolar patients ([@B4]). Finally, we did not assess neurocognitive function in this sample, so the functional significance of these hippocampal alterations remains to be established.

One prior study ([@B2]) has assessed the relationship between regional hippocampal morphology and memory performance in elderly depressed patients, using the CVLT (California Verbal Learning Test). This study found a strong correlation between delayed verbal memory and left-sided regional atrophy in the CA1 subfield and subiculum in patients with late-onset depression, which may resemble the patterns found in early Alzheimer\'s disease. However, these elderly depressed patients did not show deficits on memory measures relative to comparison subjects, suggesting that regional hippocampal atrophy patterns and their associations with memory performance could become apparent before clinical evidence of cognitive decline. Although it is unknown whether this sample of relatively young, unmedicated depressed patients suffered from memory impairment at the time of the present study, the patterns of localized atrophy we found in relation to depression severity are highly consistent with the regional findings of [@B2], suggesting that hippocampal CA1 subfields and the subiculum may be particularly vulnerable to the effects of depression. Hypercortisolaemia and ischaemia have both been hypothesized to contribute to hippocampal damage in major depression ([@B21]; [@B31]). It has also been proposed that impaired neurogenesis may contribute to mood symptoms in major depression ([@B30]). Although admittedly speculative, this may be the mechanism underlying our finding of more pronounced hippocampal deficits associated with increasing depression severity. However, whether these changes are reversible with symptomatic improvement is unknown. Longitudinal studies are clearly needed to better understand the time course of hippocampal changes in relation to symptomatic and cognitive changes in major depressive illness.

Online data
===========

###### Supplementary data
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